Secondary indication in the works as noted in last quarterly call now that the Phase III for the IIH is up and running.
This could come at any point now, as previous work was completed in 2020 for a hypothesised secondary indication but was put on back burner to prioritise Phase III launch.
Mooted secondary indications are in Acute Stroke, TBI and Hydrocephalus (all of which double or quadruple+ our current TAM, but with very similar hypothesised MOA)
In my view, this ann would magnify the upside, diversify the clinical catalyst downside, and warrant a strong rerate from the current $3M EV doldrums.
Twiggy's Invex Therapeutics | The Imminent Coin Flip, page-175
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable